Cardiology in Review:
March/April 2012 - Volume 20 - Issue 2 - p 90–95
doi: 10.1097/CRD.0b013e31823424be
New Therapy Update
Mipomersen: A Safe and Effective Antisense Therapy Adjunct to Statins in Patients With Hypercholesterolemia
Ricotta, Daniel N. MD*; Frishman, William MD†
Abstract
Mipomersen is an antisense oligonucleotide inhibitor of apolipoprotein (apo) B-100 currently in phase 3 of development for the treatment of hyperlipidemia in patients with a high risk for cardiovascular disease. The drug acts by inhibiting the production of apoB-100, which is the structural core for all atherogenic lipids, including low-density lipoprotein cholesterol (LDL-C). The agent has been shown to produce significant reductions in LDL-C from baseline values compared with placebos. Clinical trials have demonstrated that mipomersen reduces LDL-C up to 44% in patients with familial hypercholesterolemia and patients with significantly elevated LDL despite taking maximum doses of statins. Unlike other medications that target apoB-100, such as microsomal triglyceride transfer proteins, mipomersen does not cause hepatic steatosis or intestinal steatosis and does not affect dietary fat absorption. Adverse side effects encountered with mipomersen include flu-like symptoms, injection site reactions, and elevated liver transaminases. If future studies continue to show such promising results, mipomersen would likely be a viable additional lipid-lowering therapy for patients who are at high cardiovascular risk, intolerant to statins, and/or not at target lipid levels despite maximum doses of statin therapy. Clinical outcome studies looking at cardiovascular disease end points still need to be done.
© 2012 Lippincott Williams & Wilkins, Inc
In other words ATL 1101,1102,1103 can be like MIPOMERSEN."multifunctional"=$$$$$,big!
- Forums
- ASX - By Stock
- PER
- isis gathering momentum
isis gathering momentum, page-101
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
|
|||||
Last
8.2¢ |
Change
0.002(2.50%) |
Mkt cap ! $73.92M |
Open | High | Low | Value | Volume |
8.0¢ | 8.2¢ | 7.9¢ | $16.80K | 210.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 24999 | 7.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.3¢ | 31992 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 24999 | 0.079 |
2 | 60000 | 0.078 |
2 | 114144 | 0.077 |
2 | 46800 | 0.075 |
1 | 100000 | 0.074 |
Price($) | Vol. | No. |
---|---|---|
0.083 | 31992 | 1 |
0.084 | 100000 | 1 |
0.085 | 136669 | 3 |
0.086 | 33375 | 2 |
0.087 | 531562 | 3 |
Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |